Published in Handb Exp Pharmacol on January 01, 2009
Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta (2010) 1.53
Functionalized congeners of A3 adenosine receptor-selective nucleosides containing a bicyclo[3.1.0]hexane ring system. J Med Chem (2009) 1.10
G protein-coupled adenosine (P1) and P2Y receptors: ligand design and receptor interactions. Purinergic Signal (2012) 1.00
2-Dialkynyl derivatives of (N)-methanocarba nucleosides: 'Clickable' A(3) adenosine receptor-selective agonists. Bioorg Med Chem (2009) 0.95
Predicted structures of agonist and antagonist bound complexes of adenosine A3 receptor. Proteins (2011) 0.84
Multivalent dendrimeric and monomeric adenosine agonists attenuate cell death in HL-1 mouse cardiomyocytes expressing the A(3) receptor. Biochem Pharmacol (2010) 0.82
Cancer driver-passenger distinction via sporadic human and dog cancer comparison: a proof-of-principle study with colorectal cancer. Oncogene (2013) 0.80
Structure-Activity Analysis of Biased Agonism at the Human Adenosine A3 Receptor. Mol Pharmacol (2016) 0.75
International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev (2001) 9.90
Adenosine receptors as therapeutic targets. Nat Rev Drug Discov (2006) 6.15
Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor. Proc Natl Acad Sci U S A (1992) 3.91
Beta2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. J Biol Chem (2002) 2.87
Structure-activity relationships of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists. J Med Chem (1994) 2.47
2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors. J Med Chem (1994) 2.10
Nucleosides with a twist. Can fixed forms of sugar ring pucker influence biological activity in nucleosides and oligonucleotides? J Med Chem (1996) 2.08
Molecular cloning and characterization of the human A3 adenosine receptor. Proc Natl Acad Sci U S A (1993) 2.08
Structural determinants of A(3) adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary. J Med Chem (2002) 1.97
A binding site model and structure-activity relationships for the rat A3 adenosine receptor. Mol Pharmacol (1994) 1.87
Pharmacological characterization of novel A3 adenosine receptor-selective antagonists. Neuropharmacology (1997) 1.86
N6-Substituted adenosine derivatives: selectivity, efficacy, and species differences at A3 adenosine receptors. Biochem Pharmacol (2003) 1.82
Modeling the adenosine receptors: comparison of the binding domains of A2A agonists and antagonists. J Med Chem (2003) 1.70
Methanocarba analogues of purine nucleosides as potent and selective adenosine receptor agonists. J Med Chem (2000) 1.65
Direct preconditioning of cultured chick ventricular myocytes. Novel functions of cardiac adenosine A2a and A3 receptors. J Clin Invest (1996) 1.57
(N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists. J Med Chem (2005) 1.54
Molecular cloning of a novel putative G-protein coupled receptor expressed during rat spermiogenesis. FEBS Lett (1991) 1.53
A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett (1993) 1.51
Exploring distal regions of the A3 adenosine receptor binding site: sterically constrained N6-(2-phenylethyl)adenosine derivatives as potent ligands. Bioorg Med Chem (2004) 1.34
Agonist-occupied A3 adenosine receptors exist within heterogeneous complexes in membrane microdomains of individual living cells. FASEB J (2007) 1.32
The A3 adenosine receptor: an enigmatic player in cell biology. Pharmacol Ther (2007) 1.32
Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. J Med Chem (1998) 1.32
Derivatives of the triazoloquinazoline adenosine antagonist (CGS15943) are selective for the human A3 receptor subtype. J Med Chem (1996) 1.31
Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models. J Rheumatol (2005) 1.27
Ring-Constrained (N)-methanocarba nucleosides as adenosine receptor agonists: independent 5'-uronamide and 2'-deoxy modifications. Bioorg Med Chem Lett (2001) 1.26
Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors. J Med Chem (1995) 1.26
Structure-activity relationships of 2-chloro-N6-substituted-4'-thioadenosine-5'-uronamides as highly potent and selective agonists at the human A3 adenosine receptor. J Med Chem (2006) 1.25
N(6)-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A(3) receptor and a starting point for searching A(2B) ligands. J Med Chem (2002) 1.22
"Reversine" and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem (2005) 1.21
Neoceptor concept based on molecular complementarity in GPCRs: a mutant adenosine A(3) receptor with selectively enhanced affinity for amine-modified nucleosides. J Med Chem (2001) 1.21
Thiazole and thiadiazole analogues as a novel class of adenosine receptor antagonists. J Med Chem (2001) 1.21
Discovery of a new nucleoside template for human A3 adenosine receptor ligands: D-4'-thioadenosine derivatives without 4'-hydroxymethyl group as highly potent and selective antagonists. J Med Chem (2007) 1.18
Progress in the pursuit of therapeutic adenosine receptor antagonists. Med Res Rev (2006) 1.18
The cross-species A3 adenosine-receptor antagonist MRS 1292 inhibits adenosine-triggered human nonpigmented ciliary epithelial cell fluid release and reduces mouse intraocular pressure. Curr Eye Res (2005) 1.17
Selective A(3) adenosine receptor antagonists derived from nucleosides containing a bicyclo[3.1.0]hexane ring system. Bioorg Med Chem (2008) 1.16
Novel N6-substituted adenosine 5'-N-methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury. Am J Physiol Heart Circ Physiol (2003) 1.15
[(3)H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors. Mol Pharmacol (2000) 1.12
2-Substituted adenosine derivatives: affinity and efficacy at four subtypes of human adenosine receptors. Biochem Pharmacol (2004) 1.11
Conversion of A3 adenosine receptor agonists into selective antagonists by modification of the 5'-ribofuran-uronamide moiety. Bioorg Med Chem Lett (2005) 1.09
Exploring QSAR of thiazole and thiadiazole derivatives as potent and selective human adenosine A3 receptor antagonists using FA and GFA techniques. Bioorg Med Chem (2005) 1.08
Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists. Bioorg Med Chem Lett (2008) 1.07
[(3)H]8-Ethyl-4-methyl-2-phenyl-(8R)-4,5,7,8-tetrahydro-1H-imidazo[2,1-i]-purin-5-one ([(3)H]PSB-11), a novel high-affinity antagonist radioligand for human A(3) adenosine receptors. Bioorg Med Chem Lett (2002) 1.07
Structure-activity relationships of thiazole and thiadiazole derivatives as potent and selective human adenosine A3 receptor antagonists. Bioorg Med Chem (2004) 1.07
Structure-activity relationships of 9-alkyladenine and ribose-modified adenosine derivatives at rat A3 adenosine receptors. J Med Chem (1995) 1.06
Medicinal chemistry of adenosine A3 receptor ligands. Curr Top Med Chem (2003) 1.05
Selective ligands for rat A3 adenosine receptors: structure-activity relationships of 1,3-dialkylxanthine 7-riboside derivatives. J Med Chem (1994) 1.05
Modulation of adenosine receptor affinity and intrinsic efficacy in adenine nucleosides substituted at the 2-position. Bioorg Med Chem (2004) 1.05
A3 adenosine receptors and mitogen-activated protein kinases in lung injury following in vivo reperfusion. Crit Care (2006) 1.03
2-triazole-substituted adenosines: a new class of selective A3 adenosine receptor agonists, partial agonists, and antagonists. J Med Chem (2006) 1.02
Activation of A(3)adenosine receptor protects against doxorubicin-induced cardiotoxicity. J Mol Cell Cardiol (2001) 1.02
Allosteric modulation of the adenosine family of receptors. Mini Rev Med Chem (2005) 1.02
Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists. J Med Chem (2003) 1.00
2,5'-Disubstituted adenosine derivatives: evaluation of selectivity and efficacy for the adenosine A(1), A(2A), and A(3) receptor. J Med Chem (2002) 1.00
3'-Aminoadenosine-5'-uronamides: discovery of the first highly selective agonist at the human adenosine A3 receptor. J Med Chem (2003) 1.00
Structure-activity relationships of 2-chloro-N6-substituted-4'-thioadenosine-5'-N,N-dialkyluronamides as human A3 adenosine receptor antagonists. Bioorg Med Chem Lett (2008) 0.99
A neoceptor approach to unraveling microscopic interactions between the human A2A adenosine receptor and its agonists. Chem Biol (2005) 0.99
Synthesis, biological properties, and molecular modeling investigation of the first potent, selective, and water-soluble human A(3) adenosine receptor antagonist. J Med Chem (2002) 0.99
Structure-activity relationships of adenosine A3 receptor ligands: new potential therapy for the treatment of glaucoma. Bioorg Med Chem Lett (2004) 0.99
Docking studies of agonists and antagonists suggest an activation pathway of the A3 adenosine receptor. J Mol Graph Model (2006) 0.99
Isoquinoline and quinazoline urea analogues as antagonists for the human adenosine A(3) receptor. J Med Chem (2000) 0.97
Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: A complete structure-activity profile. Purinergic Signal (2006) 0.96
Adenosine A3 receptors are located in neurons of the rat hippocampus. Neuroreport (2003) 0.95
Activity of the A3 adenosine receptor gene promoter in transgenic mice: characterization of previously unidentified sites of expression. FEBS Lett (2002) 0.94
Structure-activity relationships of new 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric enhancers of the A3 adenosine receptor. J Med Chem (2006) 0.94
Interactions of flavonoids and other phytochemicals with adenosine receptors. J Med Chem (1996) 0.90
N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem (2007) 0.89
Differential effect of adenosine on tumor and normal cell growth: focus on the A3 adenosine receptor. J Cell Physiol (2001) 0.88
Pharmacophore based receptor modeling: the case of adenosine A3 receptor antagonists. An approach to the optimization of protein models. J Med Chem (2006) 0.88
Orthogonal activation of the reengineered A3 adenosine receptor (neoceptor) using tailored nucleoside agonists. J Med Chem (2006) 0.88
Role of adenosine A3 receptors on CA1 hippocampal neurotransmission during oxygen-glucose deprivation episodes of different duration. Biochem Pharmacol (2007) 0.86
Ligand and structure-based methodologies for the prediction of the activity of G protein-coupled receptor ligands. J Comput Aided Mol Des (2008) 0.84
The synthesis of highly potent, selective, and water-soluble agonists at the human adenosine A3 receptor. Bioorg Med Chem Lett (2006) 0.84
Pyrazolo-triazolo-pyrimidine derivatives as adenosine receptor antagonists: a possible template for adenosine receptor subtypes? Curr Pharm Des (2002) 0.84
Design, synthesis, and biological activity of N6-substituted-4'-thioadenosines at the human A3 adenosine receptor. Bioorg Med Chem (2006) 0.83
Imidazo[2,1-i]purin-5-ones and related tricyclic water-soluble purine derivatives: potent A(2A)- and A(3)-adenosine receptor antagonists. J Med Chem (2002) 0.83
2-Pyrazolyl-N(6)-substituted adenosine derivatives as high affinity and selective adenosine A(3) receptor agonists. J Med Chem (2004) 0.83
Exploring human adenosine A3 receptor complementarity and activity for adenosine analogues modified in the ribose and purine moiety. Bioorg Med Chem (2005) 0.82
A series of ligands displaying a remarkable agonistic-antagonistic profile at the adenosine A1 receptor. J Med Chem (2005) 0.82
2-Phenylimidazo[2,1-i]purin-5-ones: structure-activity relationships and characterization of potent and selective inverse agonists at Human A3 adenosine receptors. Bioorg Med Chem (2003) 0.81
4-amido-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-ones as new potent and selective human A3 adenosine receptor antagonists. synthesis, pharmacological evaluation, and ligand-receptor modeling studies. J Med Chem (2006) 0.81
Synthesis of hypermodified adenosine derivatives as selective adenosine A3 receptor ligands. Bioorg Med Chem (2005) 0.81
2-(Benzimidazol-2-yl)quinoxalines: a novel class of selective antagonists at human A(1) and A(3) adenosine receptors designed by 3D database searching. J Med Chem (2005) 0.80
Synthesis and structure-activity relationships of a new set of 2-arylpyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists. J Med Chem (2000) 0.80
New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies. J Med Chem (2007) 0.80
KF26777 (2-(4-bromophenyl)-7,8-dihydro-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one dihydrochloride), a new potent and selective adenosine A3 receptor antagonist. Eur J Pharmacol (2002) 0.79
1,2,4-Triazolo[5,1-i]purine derivatives as highly potent and selective human adenosine A(3) receptor ligands. J Med Chem (2002) 0.79
Pyrido[2,1-f]purine-2,4-dione derivatives as a novel class of highly potent human A(3) adenosine receptor antagonists. J Med Chem (2002) 0.78
New 2-arylpyrazolo[4,3-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. J Med Chem (2005) 0.78
New pyrrolo[2,1-f]purine-2,4-dione and imidazo[2,1-f]purine-2,4-dione derivatives as potent and selective human A3 adenosine receptor antagonists. J Med Chem (2005) 0.78
N6-ethyl-2-alkynyl NECAs, selective human A3 adenosine receptor agonists. Bioorg Med Chem Lett (2006) 0.77
New highly potent and selective adenosine A(3) receptor antagonists. Curr Top Med Chem (2004) 0.76
Impact of the aryl substituent kind and distance from pyrimido[2,1-f]purindiones on the adenosine receptor selectivity and antagonistic properties. Eur J Med Chem (2003) 0.76
5-amino-2-phenyl[1,2,3]triazolo[1,2-a][1,2,4]benzotriazin-1-one: a versatile scaffold to obtain potent and selective A3 adenosine receptor antagonists. J Med Chem (2007) 0.76
Facile synthesis of fused 1,2,4-triazolo[1,5-c]pyrimidine derivatives as human adenosine A3 receptor ligands. Bioorg Med Chem Lett (2004) 0.76
Cigarette smoke-induced neurogenic inflammation is mediated by alpha,beta-unsaturated aldehydes and the TRPA1 receptor in rodents. J Clin Invest (2008) 2.20
The 'headache tree' via umbellulone and TRPA1 activates the trigeminovascular system. Brain (2011) 1.70
DNA minor groove binders as potential antitumor and antimicrobial agents. Med Res Rev (2004) 1.54
A glance at adenosine receptors: novel target for antitumor therapy. Pharmacol Ther (2003) 1.41
Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation. Pain (2011) 1.35
Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells. Mol Pharmacol (2007) 1.28
Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells. J Invest Dermatol (2002) 1.27
"Reversine" and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem (2005) 1.21
Controlling murine and rat chronic pain through A3 adenosine receptor activation. FASEB J (2012) 1.20
Discovery of a new nucleoside template for human A3 adenosine receptor ligands: D-4'-thioadenosine derivatives without 4'-hydroxymethyl group as highly potent and selective antagonists. J Med Chem (2007) 1.18
Structure activity and molecular modeling analyses of ribose- and base-modified uridine 5'-triphosphate analogues at the human P2Y2 and P2Y4 receptors. Biochem Pharmacol (2005) 1.18
Development of selective agonists and antagonists of P2Y receptors. Purinergic Signal (2008) 1.17
Systematic investigation of polyamidoamine dendrimers surface-modified with poly(ethylene glycol) for drug delivery applications: synthesis, characterization, and evaluation of cytotoxicity. Bioconjug Chem (2008) 1.17
Toward multivalent signaling across G protein-coupled receptors from poly(amidoamine) dendrimers. Bioconjug Chem (2008) 1.13
Structure-activity relationship of uridine 5'-diphosphoglucose analogues as agonists of the human P2Y14 receptor. J Med Chem (2007) 1.12
Functionalized congeners of A3 adenosine receptor-selective nucleosides containing a bicyclo[3.1.0]hexane ring system. J Med Chem (2009) 1.10
Conversion of A3 adenosine receptor agonists into selective antagonists by modification of the 5'-ribofuran-uronamide moiety. Bioorg Med Chem Lett (2005) 1.09
Synthesis and antitumor activity of 1,5-disubstituted 1,2,4-triazoles as cis-restricted combretastatin analogues. J Med Chem (2010) 1.06
The P2X7 receptor as a therapeutic target. Expert Opin Ther Targets (2008) 1.05
Leukocyte P2 receptors: a novel target for anti-inflammatory and anti-tumor therapy. Curr Drug Targets Cardiovasc Haematol Disord (2005) 1.05
Synthesis and biological evaluation of 2- and 3-aminobenzo[b]thiophene derivatives as antimitotic agents and inhibitors of tubulin polymerization. J Med Chem (2007) 1.04
Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents. J Med Chem (2010) 1.03
Activation of TRPA1 on dural afferents: a potential mechanism of headache pain. Pain (2012) 1.03
Molecular recognition in the P2Y(14) receptor: Probing the structurally permissive terminal sugar moiety of uridine-5'-diphosphoglucose. Bioorg Med Chem (2009) 1.01
Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists. J Med Chem (2003) 1.00
Structure-activity relationships of 2-chloro-N6-substituted-4'-thioadenosine-5'-N,N-dialkyluronamides as human A3 adenosine receptor antagonists. Bioorg Med Chem Lett (2008) 0.99
Hypoxia inhibits paclitaxel-induced apoptosis through adenosine-mediated phosphorylation of bad in glioblastoma cells. Mol Pharmacol (2007) 0.99
Structure-activity relationships of truncated D- and l-4'-thioadenosine derivatives as species-independent A3 adenosine receptor antagonists. J Med Chem (2008) 0.99
Synthesis, biological properties, and molecular modeling investigation of the first potent, selective, and water-soluble human A(3) adenosine receptor antagonist. J Med Chem (2002) 0.99
Defining amino acid residues involved in DNA-protein interactions and revelation of 3'-exonuclease activity in endonuclease V. Biochemistry (2005) 0.98
Synthesis and evaluation of 1,5-disubstituted tetrazoles as rigid analogues of combretastatin A-4 with potent antiproliferative and antitumor activity. J Med Chem (2011) 0.97
A(3) adenosine receptors in human neutrophils and promyelocytic HL60 cells: a pharmacological and biochemical study. Mol Pharmacol (2002) 0.97
Rational design of sulfonated A3 adenosine receptor-selective nucleosides as pharmacological tools to study chronic neuropathic pain. J Med Chem (2013) 0.96
Rational design, synthesis, and evaluation of key analogues of CC-1065 and the duocarmycins. J Am Chem Soc (2007) 0.95
Hybrid molecules between distamycin A and active moieties of antitumor agents. Bioorg Med Chem (2006) 0.95
New strategies for the synthesis of A3 adenosine receptor antagonists. Bioorg Med Chem (2003) 0.95
Pyrimidine ribonucleotides with enhanced selectivity as P2Y(6) receptor agonists: novel 4-alkyloxyimino, (S)-methanocarba, and 5'-triphosphate gamma-ester modifications. J Med Chem (2010) 0.95
Structural and conformational requisites in DNA quadruplex groove binding: another piece to the puzzle. J Am Chem Soc (2010) 0.95
The selective A2A receptor antagonist SCH 58261 protects from neurological deficit, brain damage and activation of p38 MAPK in rat focal cerebral ischemia. Brain Res (2006) 0.94
Stereoselective functionalization of the 1'-position of 4'-thionucleosides. Org Lett (2006) 0.93
Active site plasticity of endonuclease V from Salmonella typhimurium. Biochemistry (2005) 0.93
Design, synthesis, and biological evaluation of thiophene analogues of chalcones. Bioorg Med Chem (2008) 0.93
Adenosine modulates HIF-1{alpha}, VEGF, IL-8, and foam cell formation in a human model of hypoxic foam cells. Arterioscler Thromb Vasc Biol (2009) 0.93
Convergent synthesis and biological evaluation of 2-amino-4-(3',4',5'-trimethoxyphenyl)-5-aryl thiazoles as microtubule targeting agents. J Med Chem (2011) 0.92
Expression, pharmacological profile, and functional coupling of A2B receptors in a recombinant system and in peripheral blood cells using a novel selective antagonist radioligand, [3H]MRE 2029-F20. Mol Pharmacol (2005) 0.92
Enhanced potency of nucleotide-dendrimer conjugates as agonists of the P2Y14 receptor: multivalent effect in G protein-coupled receptor recognition. Bioconjug Chem (2009) 0.91
A(2B) and A(3) adenosine receptors modulate vascular endothelial growth factor and interleukin-8 expression in human melanoma cells treated with etoposide and doxorubicin. Neoplasia (2009) 0.91
Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists. J Med Chem (2004) 0.91
A3 adenosine receptors modulate hypoxia-inducible factor-1alpha expression in human A375 melanoma cells. Neoplasia (2005) 0.90
Synthesis and biological evaluation of 2-(3',4',5'-trimethoxybenzoyl)-3-amino 5-aryl thiophenes as a new class of tubulin inhibitors. J Med Chem (2006) 0.89
Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors. Biochem Pharmacol (2005) 0.89
Stereoselective synthesis of 2'-C-methyl-cyclopropyl-fused carbanucleosides as potential anti-HCV agents. Org Lett (2006) 0.89
Synthesis and biological evaluation of 2-amino-3-(4-chlorobenzoyl)-4-[N-(substituted) piperazin-1-yl]thiophenes as potent allosteric enhancers of the A1 adenosine receptor. J Med Chem (2008) 0.89
TR-644 a novel potent tubulin binding agent induces impairment of endothelial cells function and inhibits angiogenesis. Angiogenesis (2013) 0.88
Probing the binding site of the A1 adenosine receptor reengineered for orthogonal recognition by tailored nucleosides. Biochemistry (2007) 0.88
Allosteric enhancers for A1 adenosine receptor. Mini Rev Med Chem (2007) 0.88
Pharmacophore based receptor modeling: the case of adenosine A3 receptor antagonists. An approach to the optimization of protein models. J Med Chem (2006) 0.88
Probing distal regions of the A2B adenosine receptor by quantitative structure-activity relationship modeling of known and novel agonists. J Med Chem (2008) 0.88
Application of the functionalized congener approach to dendrimer-based signaling agents acting through A(2A) adenosine receptors. Purinergic Signal (2008) 0.87
Adenosine A(2A) receptor dynamics studied with the novel fluorescent agonist Alexa488-APEC. Eur J Pharmacol (2008) 0.87
Modulation of metalloproteinase-9 in U87MG glioblastoma cells by A3 adenosine receptors. Biochem Pharmacol (2010) 0.86
Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem (2007) 0.86
Design, synthesis and structure-activity relationship of 2-(3',4',5'-trimethoxybenzoyl)-benzo[b]furan derivatives as a novel class of inhibitors of tubulin polymerization. Bioorg Med Chem (2009) 0.86
Hybrid alpha-bromoacryloylamido chalcones. Design, synthesis and biological evaluation. Bioorg Med Chem Lett (2009) 0.86
N(6)-[(hetero)aryl/(cyclo)alkyl-carbamoyl-methoxy-phenyl]-(2-chloro)-5'-N-ethylcarboxamido-adenosines: the first example of adenosine-related structures with potent agonist activity at the human A(2B) adenosine receptor. Bioorg Med Chem (2007) 0.86
GPCR ligand dendrimer (GLiDe) conjugates: adenosine receptor interactions of a series of multivalent xanthine antagonists. Bioconjug Chem (2011) 0.86
Synthesis and biological evaluation of 1-methyl-2-(3',4',5'-trimethoxybenzoyl)-3-aminoindoles as a new class of antimitotic agents and tubulin inhibitors. J Med Chem (2008) 0.86
Recent improvements in the development of A(2B) adenosine receptor agonists. Purinergic Signal (2008) 0.86
Synthesis and biological evaluation of 2-amino-3-(3',4',5'-trimethoxybenzoyl)-5-aryl thiophenes as a new class of potent antitubulin agents. J Med Chem (2006) 0.85
Synthesis and biological evaluation of 2-(alkoxycarbonyl)-3-anilinobenzo[b]thiophenes and thieno[2,3-b]pyridines as new potent anticancer agents. J Med Chem (2013) 0.85
Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners. J Med Chem (2004) 0.85
Recent developments in A2B adenosine receptor ligands. Handb Exp Pharmacol (2009) 0.84
Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications. J Med Chem (2012) 0.84
Recent improvements in the development of A(2B) adenosine receptor agonists. Purinergic Signal (2009) 0.84
Synthesis and biological evaluation of 2-(3',4',5'-trimethoxybenzoyl)-3-N,N-dimethylamino benzo[b]furan derivatives as inhibitors of tubulin polymerization. Bioorg Med Chem (2008) 0.84
2-Arylamino-4-amino-5-aroylthiazoles. "One-pot" synthesis and biological evaluation of a new class of inhibitors of tubulin polymerization. J Med Chem (2009) 0.84
N-Arylpiperazine modified analogues of the P2X7 receptor KN-62 antagonist are potent inducers of apoptosis of human primary osteoclasts. J Biomed Sci (2005) 0.83
Agonists and antagonists for P2 receptors. Novartis Found Symp (2006) 0.83
Modulation of the Akt/Ras/Raf/MEK/ERK pathway by A₃ adenosine receptor. Purinergic Signal (2006) 0.83
[3H]-MRE 2029-F20, a selective antagonist radioligand for the human A2B adenosine receptors. Bioorg Med Chem Lett (2004) 0.83
Antinociceptive effects of the selective CB2 agonist MT178 in inflammatory and chronic rodent pain models. Pain (2013) 0.82
Characterization by flow cytometry of fluorescent, selective agonist probes of the A(3) adenosine receptor. Biochem Pharmacol (2013) 0.82
The blockade of transient receptor potential ankirin 1 (TRPA1) signalling mediates antidepressant- and anxiolytic-like actions in mice. Br J Pharmacol (2014) 0.82
Synthesis of novel antimitotic agents based on 2-amino-3-aroyl-5-(hetero)arylethynyl thiophene derivatives. Bioorg Med Chem Lett (2010) 0.81